Atrium Therapeutics, Inc. (RNA) stock
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.64+0.16 (+2.47%)
Close on Nov 18, 2026Market cap $113.58MP/E –Yield –
Atrium Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $13.80M | +3.8% |
| Q2 FY2026 | Jun 30, 2026 | $15.34M | +121.2% |
| Q1 FY2026 | Mar 31, 2026 | $16.66M | – |
| Q3 FY2025 | Sep 30, 2025 | $9.75M | – |
| Q2 FY2025 | Jun 30, 2025 | $13.29M | – |
| Q1 FY2025 | Mar 31, 2025 | $6.94M | – |
See a number that looks wrong?